4.6 Article

Caregiver availability and patient access to hematopoietic cell transplantation: social worker perspectives inform practice

Journal

SUPPORTIVE CARE IN CANCER
Volume 27, Issue 11, Pages 4253-4264

Publisher

SPRINGER
DOI: 10.1007/s00520-019-04696-2

Keywords

Hematopoietic cell transplantation; Caregiver; Caregiver availability; Access to transplant

Funding

  1. National Marrow Donor Program's System Capacity Initiative Program

Ask authors/readers for more resources

Purpose Hematopoietic cell transplantation (HCT) often involves a long hospitalization and recovery period, with patients generally required to have a caregiver. This study aimed to identify transplant center (TC) requirements for a caregiver, describe challenges that impact caregiver availability, and identify potential solutions. Methods An exploratory sequential mixed-methods approach was used. Qualitative data was obtained from focus groups of TC social workers in the United States (US) (three focus groups; n = 15 total participants). Results informed the development of a national, web-based survey that was administered to the primary social worker contact at TCs in the National Marrow Donor Program (NMDP)/Be The Match Network (n = 133). Results Respondents included social workers from adult (n = 47) and pediatric (n = 19) TCs (response rate = 49%). The majority (89%) of both adult and pediatric TCs required a caregiver for a patient to proceed to transplant, but requirements varied in length of time, formality, transplant type, and HCT setting. Regardless of transplant type or patient population, social workers identified loss of caregiver income as the greatest challenge to caregiver availability, with the most common solution being allowing patients to have multiple caregivers throughout the transplant course. Discussion Caregiver availability is an important concern for patients considering and receiving HCT, and may be a barrier proceeding to HCT when a caregiver is unavailable. Results from this study highlight caregiver availability barriers and solutions of TCs across the US. These results can inform TCs about other center experiences with caregiver availability and identify potential practice changes for individual TCs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Fecal microbiota of adolescent and young adult cancer survivors and metabolic syndrome: an exploratory study

Seth J. Rotz, Naseer Sangwan, Matthew Nagy, Alice Tzeng, Margaret Jia, Maria Moncaliano, Navneet S. Majhail, Charis Eng

Summary: The intestinal microbiome diversity of long-term survivors of pediatric cancer is reduced, and radiation therapy may further decrease the diversity. The microbiome composition is associated with metabolic syndrome, obesity, and chronic inflammation in these survivors.

PEDIATRIC HEMATOLOGY AND ONCOLOGY (2022)

Letter Biophysics

Pattern of somatic mutation changes after allogeneic hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes

Sanghee Hong, Lisa Rybicki, Carmelo Gurnari, Simona Pagliuca, Aiwen Zhang, Dawn Thomas, Valeria Visconte, Jibran Durrani, Ronald M. Sobecks, Matt Kalaycio, Aaron T. Gerds, Hetty E. Carraway, Sudipto Mukherjee, Mikkael A. Sekeres, Anjali S. Advani, Navneet S. Majhail, Betty K. Hamilton, Bhumika J. Patel, Jaroslaw P. Maciejewski

BONE MARROW TRANSPLANTATION (2022)

Article Oncology

Post-transplant cyclophosphamide pharmacokinetics and haploidentical hematopoietic cell transplantation outcomes: an exploratory study

Kripa Shanker Kasudhan, Amol N. Patil, Aditya Jandial, Alka Khadwal, Gaurav Prakash, Arihant Jain, Dinesh Bhurani, Rayaz Ahmed, Narendra Agrawal, Reema Singh, Man Updesh Singh Sachdeva, Neelam Varma, Reena Das, Savita Verma Attri, Samir Malhotra, Navneet S. Majhail, Pankaj Malhotra, Deepesh P. Lad

Summary: This study investigated the pharmacokinetics of cyclophosphamide in haploidentical transplantation and found an association between CEPM AUC(0-48) and severe chronic GVHD and GRFS.

LEUKEMIA & LYMPHOMA (2022)

Article Oncology

Toxicity analysis of busulfan pharmacokinetic therapeutic dose monitoring

Kelly J. Gaffney, Theresa A. Urban, Mariana Lucena, Faiz Anwer, Robert M. Dean, Aaron T. Gerds, Betty K. Hamilton, Deepa Jagadeesh, Matt E. Kalaycio, Jack Khouri, Brad Pohlman, Ronald Sobecks, Allison Winter, Lisa Rybicki, Navneet S. Majhail, Brian T. Hill

Summary: Pharmacokinetic-guided therapeutic drug monitoring may be a safe practice in stem cell transplant recipients receiving busulfan conditioning regimens. Most patients in the therapeutic drug monitoring group required dose adjustments and there was no significant difference in toxicity compared to those receiving weight-based dose.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2022)

Letter Biophysics

Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel

Agrima Mian, Wei Wei, Betty K. Hamilton, Allison M. Winter, Jack Khouri, Brad Pohlman, Aaron T. Gerds, Deepa Jagadeesh, Faiz Anwer, Matt Kalaycio, Robert M. Dean, Ronald Sobecks, Paolo F. Caimi, Brian T. Hill, Navneet S. Majhail

BONE MARROW TRANSPLANTATION (2023)

Article Hematology

Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis

Brittany Knick Ragon, Mithun Vinod Shah, Anita D'Souza, Noel Estrada-Merly, Lohith Gowda, Gemlyn George, Marcos de Lima, Shahrukh Hashmi, Mohamed A. Kharfan-Dabaja, Navneet S. Majhail, Rahul Banerjee, Ayman Saad, Gerhard C. Hildebrandt, Hira Mian, Muhammad Bilal Abid, Minoo Battiwalla, Lazaros J. Lekakis, Sagar S. Patel, Hemant S. Murthy, Yago Nieto, Christopher Strouse, Sherif M. Badawy, Samer Al Hadidi, Bhagirathbhai Dholaria, Mahmoud Aljurf, David H. Vesole, Cindy H. Lee, Attaphol Pawarode, Usama Gergis, Kevin C. Miller, Leona A. Holmberg, Aimaz Afrough, Melhem Solh, Pashna N. Munshi, Taiga Nishihori, Larry D. Anderson Jr, Baldeep Wirk, Gurbakhash Kaur, Muzaffar H. Qazilbash, Nina Shah, Shaji K. Kumar, Saad Z. Usmani

Summary: The use of proteasome inhibitor and immunomodulatory drug-based combinations, followed by high-dose melphalan and autologous hematopoietic stem cell transplantation (auto-HSCT), has significantly improved the overall survival (OS) in multiple myeloma (MM) patients. However, the use of lenalidomide maintenance after auto-HSCT has been associated with an increased risk of second primary malignancies (SPM) and second hematological malignancies (SHM). This study evaluated the impact of SPM and SHM on progression-free survival (PFS) and OS in MM patients after auto-HSCT using registry data.

BLOOD ADVANCES (2023)

Article Hematology

Demographics, Motivations, and Experiences of Participants in Transplantation or Cellular Therapy Fellowships

Rahul Banerjee, Amar H. Kelkar, Urshila Durani, Theodora Anagnostou, Miki Nishitani, Kanwaldeep Mallhi, Navneet S. Majhail, Aaron C. Logan

Summary: Recent guidelines from the American Society for Transplantation and Cellular Therapy have aimed to establish expectations for participants in blood and marrow transplantation (BMT) and cellular therapy (CT) fellowships. A survey was conducted to examine the demographics, motivations, and experiences of recent participants in BMT/CT fellowships. The results showed that the fellowship training had a positive impact on participants' comfort with BMT/CT management and the majority would highly recommend this training to others.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Article Hematology

A Pilot Trial of Patient-Reported Outcomes for Acute Graft-Versus-Host-Disease

Sagar S. Patel, Sanghee Hong, Lisa Rybicki, Stephanie Farlow, Jane Dabney, Matt Kalaycio, Ronald Sobecks, Navneet S. Majhail, Betty K. Hamilton

Summary: Acute graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic cell transplantation (HCT), causing significant physical and psychosocial symptoms. This pilot study aimed to assess the feasibility of using patient-reported outcome (PRO) measures to evaluate symptom burden and quality of life (QOL) in acute GVHD. The study utilized surveys from various PRO measures and found that patients with acute GVHD had lower QOL scores compared to those without or with mild GVHD. The PRO-CTCAE captured several common symptoms of acute GVHD. Challenges in implementing PRO measures in acute GVHD were identified. Further research is needed to make PROs feasible in this patient population.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Article Hematology

Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma

Rajshekhar Chakraborty, Jean Yi, Lisa Rybicki, Jaime Preussler, Abhinav Deol, Alison Loren, Bipin Savani, Heather S. L. Jim, Jan Cerny, Jana Reynolds, Jennifer Whitten, John R. Wingard, Joseph P. McGuirk, Joseph Uberti, Nandita Khera, Patrick Stiff, Samantha M. Jaglowski, Shahrukh Hashmi, Shernan G. Holtan, Steven Devine, Theresa Hahn, Victoria L. Whalen, Wael Saber, William Wood, K. Scott Baker, Karen Syrjala, Navneet S. Majhail

Summary: Survivors of autologous hematopoietic cell transplantation (AHCT) for multiple myeloma in stable remission do not have clinically meaningful worsening in physical functioning compared to the general population. However, they may experience distress related to health burden, uncertainty, and finances. Adherence to preventive care guidelines is high, but adherence to exercise and diet guidelines is relatively low.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Article Hematology

Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy

Abraham S. Kanate, Navneet Majhail, Zachariah Defilipp, Binod Dhakal, Bhagirathbhai Dholaria, Betty Hamilton, Alex F. Herrera, Yoshihiro Inamoto, Tania Jain, Miguel -Angel Perales, Paul A. Carpenter, Mehdi Hamadani

Summary: The American Society for Transplantation and Cellular Therapy (ASTCT) has published guidelines on CAR-T therapy indications, categorizing them as standard of care and recommending only FDA-approved indications. These guidelines will be periodically updated based on new evidence.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Article Hematology

The ASTCT-NMDP ACCESS Initiative: A Collaboration to Address and Sustain Equal Outcomes for All across the Hematopoietic Cell Transplantation and Cellular Therapy Ecosystem

Jeffery J. Auletta, Brenda M. Sandmaier, Erica Jensen, Navneet S. Majhail, Jessica Knutson, Eneida Nemecek, Femina Ajayi-Hackworth, Stella M. Davies

Summary: The American Society for Transplantation and Cellular Therapy (ASTCT) and the National Marrow Donor Program (NMDP) have formed the ACCESS Initiative to address and reduce barriers to hematopoietic cell transplantation (HCT) and cellular therapy (CT) in an effort to ensure equal access and outcomes for all patients. The inaugural workshop discussed goals and provided an initial roadmap for the group's efforts.

TRANSPLANTATION AND CELLULAR THERAPY (2022)

Article Hematology

Health-Related Quality of Life in Young Adult Survivors of Hematopoietic Cell Transplantation

Seth J. Rotz, Jean C. Yi, Betty K. Hamilton, Wei Wei, Jaime M. Preussler, Jan Cerny, Abhinav Deol, Heather Jim, Nandita Khera, Theresa Hahn, Shahrukh K. Hashmi, Shernan Holtan, Samantha M. Jaglowski, Alison W. Loren, Joseph McGuirk, Jana Reynolds, Wael Saber, Bipin N. Savani, Patrick Stiff, Joseph Uberti, John R. Wingard, William A. Wood, K. Scott Baker, Navneet S. Majhail, Karen L. Syrjala

Summary: Young adult hematopoietic cell transplantation (HCT) survivors have poorer mental health, increased cancer-related distress, and lower health self-efficacy compared to older adults. Health self-efficacy is strongly associated with health-related quality of life (HRQOL), suggesting that interventions targeting self-efficacy may have a broad impact on health outcomes among young adults.

TRANSPLANTATION AND CELLULAR THERAPY (2022)

Article Hematology

Self-Efficacy for Symptom Management in Long-Term Adult Hematopoietic Stem Cell Survivors

Nosha Farhadfar, Michael T. Weaver, Zeina Al-Mansour, Jean C. Yi, Heather S. L. Jim, Alison W. Loren, Navneet S. Majhail, Victoria Whalen, Joseph Uberti, John R. Wingard, Debra Lynch Kelly, Karen L. Syrjala

Summary: The self-efficacy level of hematopoietic cell transplantation (HCT) survivors is associated with factors such as fatigue, depression, quality of life, and cancer-related distress. Lower self-efficacy is linked to higher levels of symptoms and distress, as well as lower quality of life. Therefore, improving self-efficacy in survivors is crucial for enhancing their recovery.

TRANSPLANTATION AND CELLULAR THERAPY (2022)

Article Hematology

Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation

Sagar S. Patel, Kwang Woo Ahn, Manoj Khanal, Caitrin Bupp, Mariam Allbee-Johnson, Navneet S. Majhail, Betty K. Hamilton, Seth J. Rotz, Hasan Hashem, Amer Beitinjaneh, Hillard M. Lazarus, Maxwell M. Krem, Tim Prestidge, Neel S. Bhatt, Akshay Sharma, Shahinaz M. Gadalla, Hemant S. Murthy, Larisa Broglie, Taiga Nishihori, Cesar O. Freytes, Gerhard C. Hildebrandt, Usama Gergis, Sachiko Seo, Baldeep Wirk, Marcelo C. Pasquini, Bipin N. Savani, Mohamed L. Sorror, Edward A. Stadtmauer, Saurabh Chhabra

Summary: Noninfectious pulmonary toxicity (NPT) is a significant complication of allogeneic hematopoietic cell transplantation (alloHCT), including idiopathic pneumonia syndrome (IPS), diffuse alveolar hemorrhage (DAH), and cryptogenic organizing pneumonia (COP). This study found that severe pulmonary comorbidity, acute graft-versus-host disease, mismatched unrelated donor and cord blood transplantation, and HCT Comorbidity Index (HCT-CI) score >= 1 were risk factors for developing NPT, while alloHCT performed in 2014 or later, non-total body irradiation-based conditioning, and platelet recovery were associated with a decreased risk of NPT.

TRANSPLANTATION AND CELLULAR THERAPY (2022)

Article Hematology

Comparison of Quality of Life and Outcomes between Haploidentical and Matched Related/Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Sanghee Hong, Lisa Rybicki, Linda Mclellan, Jane Dabney, Aaron T. Gerds, Seth J. Rotz, Matt Kalaycio, Rabi Hanna, Betty K. Hamilton, Navneet S. Majhail, Ronald M. Sobecks

Summary: This study compared the HRQOL between haplo-HCT and other donor sources for HCT, showing no difference in some aspects but differences in specific situations. Haplo-HCT demonstrated better emotional and functional well-being in certain conditions.

TRANSPLANTATION AND CELLULAR THERAPY (2022)

No Data Available